Therapy Areas: Devices
Zyppah cleared by US FDA for OTC sales
19 March 2019 -

Sleep apnea product company Zyppah reported on Monday the receipt of the 510k clearance from the US FDA for the launch of the first OTC (over-the-counter) dual action anti-snoring device Zyppah.

As of 21 January 2019, the company and its creator, Dr Jonathan Greenburg, DDS, received the US FDA registration #K182312 for Zyppah, which has been on the market for six years.

The company said the US FDA's certification included a "first" ranking when compared against the category monograph to feature a wholly unique, dual-action feature that advances the mandible while repositioning the tongue to keep it from blocking the airway; the reason snoring occurs.

In connection with the launch, Zyppah retails for USD99.95 and is available on Zyppah.com and Amazon.com.

Login
Username:

Password: